Infinera : Late Filing Notice (SEC Filing - NT 10-K)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Appia Energy Corp : Appia Starts Bench-Scale Monazite Processing and Metallurgical Testing with Saskatchewan Research Council
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
DUBLIN, Feb. 25, 2021 /PRNewswire/ Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2020 and introduced 2021 financial guidance. I am proud of all that the Endo team achieved in a very challenging year. We made significant progress in advancing our strategic priorities, delivered solid financial performance, rapidly responded to the COVID-19 pandemic and advanced our ESG-related actions, said Blaise Coleman, President and Chief Executive Officer at Endo. Looking ahead, we remain committed to expanding and enhancing our portfolio through focused investments, including the anticipated spring 2021 launch of QWO
Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
– Commenced enrollment in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the Phase 2 SELECT trial of Vopratelimab in combination with JTX-4014 –
– Ended 2020 with $213.2 million in cash, cash equivalents and investments –
– Company to host conference call and webcast today at 8:00 AM ET –
CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update.
“2020 proved to be a year of important pipeline execution and corporate development at Jounce despite the challenges presented by the COVID-19 pandemic. As we enter 2021, we are strongly positioned to execute on our two proof of concept studies, INNATE